- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2025, Vol. 27 ›› Issue (1): 1-12.DOI: 10.3969/j.issn.1671-2587.2025.01.001
• 专家共识 • 下一篇
中国输血协会临床输血管理学专业委员会, 中华医学会血液学分会, 中国药师协会肿瘤药师分会
收稿日期:2024-11-19
发布日期:2025-02-25
通讯作者:
李志强（上海交通大学医学院附属第六人民医院）,主任医师,硕士研究生导师,从事血液病学诊治与输血医学研究,（E-mail）kcb039@126.com。吴德沛（苏州大学附属第一医院）,主任医师,博士研究生导师,从事血液病学基础与临床研究,（E-mail）drwudepei@163.com。石军（上海交通大学医学院附属第九人民医院）,主任医师,博士研究生导师,从事血液病学基础与临床研究,（E-mail）shijun7@hotmail.com。李国辉（中国医学科学院肿瘤医院）,主任药师,硕士研究生导师,从事药学研究,（E-mail）lgh0603@cicams.ac.cn。宫济武（北京医院）,主任技师,从事输血医学研究,（E-mail）13910066259@139.com。秦莉（四川大学华西医院）,主任医师,硕士研究生导师,从事血液病学诊治与输血医学研究,（E-mail）qinli7@126.com。
作者简介:李丽玮（上海交通大学医学院附属第六人民医院）,李志强（上海交通大学医学院附属第六人民医院）,朱小玉（中国科学技术大学附属第一医院）,唐丽琴（中国科学技术大学附属第一医院）。
基金资助:
Received:2024-11-19
Published:2025-02-25
摘要： 鉴于靶向药物在肿瘤患者治疗中日益广泛的应用,为了减少靶向药物导致血液系统方面的异常,提高恶性肿瘤患者靶向药物治疗效果,减少死亡率,中国输血协会临床输血管理学专业委员会、中华医学会血液学分会和中国药师协会肿瘤药师分会共同召集了临床输血学、肿瘤学、血液病学、药学等领域的专家,通过系统查阅肿瘤学、血液病学和临床输血领域靶向药物治疗已发表文献与专家共识,以及对相关领域专家及一线医务工作者的访谈,确定本共识拟解决的10个恶性肿瘤靶向药物治疗导致血液系统异常患者输血与药物治疗相关问题,共同制定此专家共识。
中图分类号:
中国输血协会临床输血管理学专业委员会, 中华医学会血液学分会, 中国药师协会肿瘤药师分会. 靶向药物导致血液系统异常的输血与药物治疗中国专家共识*[J]. 临床输血与检验, 2025, 27(1): 1-12.
| [1] LEE Y T,TAN Y J,OON C E.Molecular targeted therapy:Treating cancer with specificity[J].Eur J Pharmacol,2018,834:188-196. [2] IMAI K,TAKAOKA A.Comparing antibody and small-molecule therapies for cancer[J].Nat Rev Cancer,2006,6(9):714-727. [3] GUYATT G H,OXMAN A D,VIST G E,et al.GRADE:an emerging consensus on rating quality of evidence and strength of recommendations[J].BMJ,2008,336(7650):924-926. [4] BROZEK J L,AKL E A,ALONSO-COELLO P,et al.Grading quality of evidence and strength of recommendations in clinical practice guidelines.Part 1 of 3.An overview of the GRADE approach and grading quality of evidence about interventions[J].Allergy,2009,64(5):669-677. [5] NATOLI C,PERRUCCI B,PERROTTI F,et al.Tyrosine kinase inhibitors[J].Curr Cancer Drug Targets,2010,10(5):462-483. [6] SHEN S H,CHEN X J,CAI J Y,et al.Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia:a randomized clinical trial[J].JAMA Oncol,2020,6(3):358-366. [7] TANIOS G E,DOLEY P B,MUNKER R.Autoimmune hemolytic Anemia associated with the use of immune checkpoint inhibitors for cancer:68 cases from the food and drug administration database and review[J].Eur J Haematol,2019,102(2):157-162. [8] JOHNSTONE P,KHAN O.Pembrolizumab-associated autoimmune haemolytic anaemia[J].BMJ Case Rep,2019,12(10):e229064. [9] TASIAN S K,ASSAD A,HUNTER D S,et al.A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia(INCB18424-269/AALL1521):dose-finding results from the part 1 safety phase[J].Blood,2018,132:555. [10] VON STACKELBERG A,LOCATELLI F,ZUGMAIER G,et al.Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia[J].J Clin Oncol,2016,34(36):4381-4389. [11] ARENA C,BIZZOCA M E,CAPONIO V C A,et al.Everolimus therapy and side-effects:a systematic review and meta-analysis[J].Int J Oncol,2021,59(1):54. [12] LEJMAN M,KUŚMIERCZUK K,BEDNARZ K,et al.Targeted therapy in the treatment of pediatric acute lymphoblastic leukemia-therapy and toxicity mechanisms[J].Int J Mol Sci,2021,22(18):9827. [13] SUGA S,KIM Y G,JOLY A,et al.Vascular endothelial growth factor(VEGF121)protects rats from renal infarction in thrombotic microangiopathy[J].Kidney Int,2001,60(4):1297-1308. [14] EREMINA V,JEFFERSON J A,KOWALEWSKA J,et al.VEGF inhibition and renal thrombotic microangiopathy[J].N Engl J Med,2008,358(11):1129-1136. [15] LI Y,GAO Z H,QU X J.The adverse effects of sorafenib in patients with advanced cancers[J].Basic Clin Pharmacol Toxicol,2015,116(3):216-221. [16] FUKUOKA K,MASACHIKA E,HONDA M,et al.Isolated metastases of hepatocellular carcinoma in the left atrium,unresponsive to treatment with sorafenib[J].Mol Clin Oncol,2015,3(2):397-399. [17] 程刚,张力.贝伐珠单抗治疗非小细胞肺癌的相关不良反应及处理原则[J].中国肺癌杂志,2010,13(6):563-567. [18] NALLURI S R,CHU D,KERESZTES R,et al.Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients[J].Jama,2008,300(19):2277. [19] 贾守薇,刘韬,黄红兵.分子靶向抗肿瘤药物的不良反应及其处理对策[J].肿瘤药学,2014,4(1):2-9. [20] 中国医师协会结直肠肿瘤专业委员会,中国抗癌协会大肠癌专业委员会,国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会.结直肠癌靶向治疗中国专家共识[J].中华普通外科学文献(电子版),2023,17(1):1-8. [21] 中华人民共和国国家卫生健康委员会.内科输血:WS/T622-2018[S/OL].(2018-09 -26)[2019-04-01].http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/10/20181025132333401.pdf. [22] CHEN C X,WANG L X,HAN B,et al.Autoimmune hemolytic Anemia in hospitalized patients:450 patients and their red blood cell transfusions[J].Medicine(Baltimore),2020,99(2):e18739. [23] 中华人民共和国卫生部,中国国家标准化管理委员会.全血及成分血质量要求: GB 18469-2012[S/OL].(2012-05-11)[2024-07-01].https://openstd.samr.gov.cn/bzgk/gb/newGbInfo?hcno=C2DC6EA87E8F0F11DE64D732F5D451EE. [24] 中国临床肿瘤学会肿瘤相关性贫血专家委员会.肿瘤相关性贫血临床实践指南(2015—2016版)[J].中国实用内科杂志,2015,35(11):921-930. [25] 中国抗癌协会肿瘤临床化疗专业委员会,中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤化疗相关贫血诊治专家共识(2019年版)[J].中国医学前沿杂志(电子版),2019,11(12):78-85. [26] CAMASCHELLA C.Iron deficiency[J].Blood,2019,133(1): 30-39. [27] PASRICHA S R,TYE-DIN J,MUCKENTHALER M U,et al.Iron deficiency[J].Lancet,2021,397(10270):233-248. [28] 中华医学会血液学分会红细胞疾病(贫血)学组.铁缺乏症和缺铁性贫血诊治和预防多学科专家共识[J].中华医学杂志,2018,98(28):2233-2237. [29] REINISCH W,STAUN M,TANDON R K,et al.A randomized,open-label,non-inferiority study of intravenous iron isomaltoside 1,000(Monofer)compared with oral iron for treatment of Anemia in IBD(PROCEED)[J].Am J Gastroenterol,2013,108(12):1877-1888. [30] MACDOUGALL I C,WHITE C,ANKER S D,et al.Intravenous iron in patients undergoing maintenance hemodialysis[J].N Engl J Med,2019,380(5):447-458. [31] CHOPRA V K,ANKER S D.Anaemia,iron deficiency and heart failure in 2020:facts and numbers[J].ESC Heart Fail,2020,7(5):2007-2011. [32] GOSDIN L,SHARMA A J,TRIPP K,et al.A school-based weekly iron and folic acid supplementation program effectively reduces Anemia in a prospective cohort of Ghanaian adolescent girls[J].J Nutr,2021,151(6):1646-1655. [33] AGRAWAL T,DEWAN P,GOMBER S,et al.Optimum dose of oral folic acid supplementation in transfusion-dependent thalassemia:a randomized controlled trial[J].J Trop Pediatr,2022,68(6):fmac087. [34] BOCCIA R V.Erythropoietic agents in chemotherapy-induced Anemia:a review of recent therapeutic progress,issues,and concerns[J].Curr Hematol Rep,2004,3(6):397-405. [35] GABRILOVE J L,CLEELAND C S,LIVINGSTON R B,et al.Clinical evaluation of once-weekly dosing of epoetin Alfa in chemotherapy patients:improvements in hemoglobin and quality of life are similar to three-times-weekly dosing[J].J Clin Oncol,2001,19(11):2875-2882. [36] CORTESI E,MANCUSO A,DE PASQUALE CERATTI A,et al.Effectiveness and safety of an induction therapy with epoetin Alfa in anemic cancer patients receiving concomitant chemotherapy[J].Oncologist,2004,9(4):459-468. [37] DEMETRI G D,KRIS M,WADE J,et al.Quality-of-life benefit in chemotherapy patients treated with epoetin Alfa is independent of disease response or tumor type:results from a prospective community oncology study.procrit study group[J].J Clin Oncol,1998,16(10):3412-3425. [38] 马军,王杰军,张力,等.EPO治疗肿瘤相关性贫血中国专家共识(2010—2011版)[J].临床肿瘤学杂志,2010,15(10):925-936. [39] PESLAK S A,OLSON T,BABUSHOK D V.Diagnosis and treatment of aplastic Anemia[J].Curr Treat Options Oncol,2017,18(12):70. [40] 靳铎,徐清华,康廷干,等.再造生血胶囊联合琥珀酸亚铁治疗气血两虚证型缺铁性贫血的疗效观察[J].现代药物与临床,2023,38(12):3102-3105. [41] HISANO M,SUZUKI R,SAGO H,et al.Vitamin B6 deficiency and Anemia in pregnancy[J].Eur J Clin Nutr,2010,64(2):221-223. [42] SEARCY K,RAINWATER S,JEROUDI M,et al.Erythropoietin-stimulating agent-resistant vitamin B6 deficiency Anemia in a pediatric patient on hemodialysis[J].Pediatr Nephrol,2021,36(2):473-476. [43] 卞竹利,乔晓红,谢晓恬,等.不同剂量丙种球蛋白辅助治疗重型再生障碍性贫血疗效分析[J].临床儿科杂志,2017,35(12):914-917. [44] ANDERSON D,ALI K,BLANCHETTE V,et al.Guidelines on the use of intravenous immune globulin for hematologic conditions[J].Transfus Med Rev,2007,21(2 Suppl 1):S9-S56. [45] 陈旭升,杨永涛.静脉输注丙种球蛋白对非新生儿溶血患儿交叉配血的影响[J].临床输血与检验,2023,25(6):749-752. [46] 邱小兰,钟昌瑞,阙庆和,等.静脉注射丙种球蛋白导致新生儿交叉配血不合一例[J].中国新生儿科杂志,2016,31(5):390. [47] SAKEM B,MATOZAN K,NYDEGGER U E,et al.Anti-red blood cell antibodies,free light chains,and antiphospholipid antibodies in intravenous immunoglobulin preparations[J].Isr Med Assoc J,2013,15(10):617-621. [48] MULDER F V M,EVERS D,DE HAAS M,et al.Severe autoimmune hemolytic Anemia;epidemiology,clinical management,outcomes and knowledge gaps[J].Front Immunol,2023,14:1228142. [49] BIRGENS H,FREDERIKSEN H,HASSELBALCH H C,et al.A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia[J].Br J Haematol,2013,163(3):393-399. [50] 江峰锦,白乐,余泽波,等.自身免疫性溶血性贫血的诊疗进展[J].临床输血与检验,2023,25(5):692-698. [51] LI X X,SHAO Y Q,GE M L,et al.A promising immunosuppressive strategy of cyclosporine alternately combined with levamisole is highly effective for moderate aplastic Anemia[J].Ann Hematol,2013,92(9):1239-1247. [52] 苏雁,吴润晖,郑杰,等.环孢素A治疗126例儿童非重型再生障碍性贫血疗效分析[J].临床儿科杂志,2015,33(5):413-416. [53] 姚雪,杨林花.利妥昔单抗治疗温抗体型自身免疫性溶血性贫血患者的研究进展[J].国际输血及血液学杂志,2023,46(6):535-539. [54] FATTIZZO B,ZANINONI A,PETTINE L,et al.Low-dose rituximab in autoimmune hemolytic Anemia:10 years after[J].Blood,2019,133(9):996-998. [55] MAUNG S W,LEAHY M,O’LEARY H M,et al.A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia[J].Br J Haematol,2013,163(1):118-122. [56] SCHIFFER C A,BOHLKE K,DELANEY M,et al.Platelet transfusion for patients with cancer:American society of clinical oncology clinical practice guideline update[J].J Clin Oncol,2018,36(3):283-299. [57] 袁响林. 肿瘤合并肝损伤患者血小板减少症管理中国专家共识(2022版)[J].临床肝胆病杂志,2023,39(6):1287-1294. [58] 郑杰,马静瑶,苏雁,等.重组人血小板生成素治疗儿童重症免疫性血小板减少症25例临床观察[J].中国实验血液学杂志,2014,22(2):393-398. [59] CIUREA S O,HOFFMAN R.Cytokines for the treatment of thrombocytopenia[J].Semin Hematol,2007,44(3):166-182. [60] MILTIADOUS O,HOU M,BUSSEL J B.Identifying and treating refractory ITP:difficulty in diagnosis and role of combination treatment[J].Blood,2020,135(7):472-490. [61] 中国临床肿瘤学会抗淋巴瘤联盟,中国临床肿瘤学会抗白血病联盟,中国临床肿瘤学会抗肿瘤药物安全管理专家委员会,等.重组人白介素-11防治血小板减少症临床应用中国专家共识(2021年版)[J].临床肿瘤学杂志,2020,25(12):1129-1137. [62] 王少怡,余自强.血小板生成素受体激动剂的研究现状及临床应用[J].国际输血及血液学杂志,2020,43(2):122-128. [63] LOZANO M L,MINGOT-CASTELLANO M E,PERERA M M,et al.Deciphering predictive factors for choice of thrombopoietin receptor agonist,treatment free responses,and thrombotic events in immune thrombocytopenia[J].Sci Rep,2019,9(1):16680. [64] ČERVINEK L,MAYER J,DOUBEK M.Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults[J].Int J Hematol,2015,102(1):7-11. [65] WU C,ZHOU X M,LIU X D.Eltrombopag-related renal vein thromboembolism in a patient with immune thrombocytopenia:a case report[J].World J Clin Cases,2021,9(11):2611-2618. [66] 曹珊珊,关月,张筱芳,等.血小板生成素受体激动剂致不良反应的文献分析[J].中国药物应用与监测,2022,19(1):34-38. [67] 中国抗癌协会临床肿瘤学协作专业委员会.肿瘤化疗所致血小板减少症诊疗中国专家共识(2014版)[J].中华肿瘤杂志,2014,36(11):876-879. [68] 秦平,魏昱,侯明,等.咖啡酸片治疗103例原发免疫性血小板减少症患者的多中心临床研究[J].中华血液学杂志,2015,36(2):103-106. [69] 纪凌云,宋婷,吴俏兰,等.国家专利中药复方治疗非重型再生障碍性贫血的用药规律分析[J].中药新药与临床药理,2023,34(10):1470-1477. [70] KARMALI R,LARSON M L,WOOLDRIDGE J E,et al.Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide,doxorubicin,vincristine,and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma[J].Leuk Lymphoma,2011,52(11):2097-2104. [71] LOGAN R M,AL-AZRI A R,BOSSI P,et al.Systematic review of growth factors and cytokines for the management of oral mucositis in cancer patients and clinical practice guidelines[J].Support Care Cancer,2020,28(5):2485-2498. [72] 李占英,王农乐,王鹤尧.rhG-CSF与rhGM-CSF的临床应用及安全性[J].药物不良反应杂志,2003,5(4):224-228. [73] BIESMA B,WILLEMSE P H,MULDER N H,et al.Effects of interleukin-3 after chemotherapy for advanced ovarian cancer[J].Blood,1992,80(5):1141-1148. [74] GANSER A,LINDEMANN A,SEIPELT G,et al.Effects of recombinant human interleukin-3 in aplastic Anemia[J].Blood,1990,76(7):1287-1292. [75] 文晓琴,关晏星.碳酸锂联合131I治疗初发格雷夫斯病合并白细胞减少症的疗效观察[J].中华核医学与分子影像杂志,2018,38(4):257-261. [76] 郭飞,黄云慧,牛慧芳,等.碳酸锂联合131I治疗毒性弥漫性甲状腺肿伴白细胞减少症疗效和安全性的系统评价[J].中国医院用药评价与分析,2020,20(9):1107-1111. [77] 朱彤,饶井芬,任艳玲,等.生血宁片联合鲨肝醇对肿瘤放化疗患者白细胞数量及细胞免疫功能的影响[J].肿瘤药学,2017,7(5):572-575. [78] 张喜平,张翔,杨红健,等.多种口服升白药物联合粒细胞集落刺激因子治疗化疗相关白细胞减少症的实验研究[J].中国中西医结合杂志,2015,35(7):860-865. [79] 李燕,陈蓉,徐新倩.芪胶升白胶囊治疗消化道恶性肿瘤化疗后骨髓抑制临床效果与安全性观察[J].中华中医药学刊,2023,41(7):235-238. [80] ZARA M,Gilbert-Dreyfus.La vitamine B4 dans la prévention et le traitement des agranulocytoses toxiques [Vitamin B4 in the prevention and treatment of toxic agranulocytosis][J].Sem Med Prof Med Soc,1958,34(33-34):970-971. [81] 耿平,李爱君,张雪伟,等.血液高凝肺癌患者应用低分子肝素后凝血功能的变化情况[J].现代肿瘤医学,2018,26(2):212-215. [82] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性心力衰竭诊断和治疗指南(1)[J].中国医刊,2010,45(8):85-89. [83] BURNETT A E,MAHAN C E,VAZQUEZ S R,et al.Guidance for the practical management of the direct oral anticoagulants(DOACs)in VTE treatment[J].J Thromb Thrombolysis,2016,41(1):206-232. [84] COLEMAN C I,TURPIE A G G,BUNZ T J,et al.Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state[J].Thromb Res,2018,163:132-137. [85] 戴辰程,何楠,肖燕燕,等.低分子肝素联合阿司匹林在儿童心导管术后股动脉血栓治疗中的效果[J].中国医药,2020,15(2):198-201. [86] 王利宏,陈君柱,郑良荣,等.阿司匹林和噻氯匹啶在射频消融治疗中对血小板活性的影响[J].中华血液学杂志,2002,23(9):492-493. [87] 中华内科杂志编辑部.规范应用阿司匹林治疗缺血性脑血管病的专家共识[J].中华内科杂志,2006,45(1):81-82. [88] KASNER S E,RANDALL B,ANDERSEN G,et al.Comparison of antiplatelet therapies for prevention of patent foramen ovale-associated stroke[J].J Stroke Cerebrovasc Dis,2020,29(4):104632. [89] 王兆钺. 凝血酶原复合物的临床应用[J].血栓与止血学,2008,14(5):238-240. [90] 宋景春,王岗,房云海,等.重症患者凝血酶原复合物合理应用中国专家共识[J].解放军医学杂志,2023,48(12):1359-1369. [91] DREBES A,DE VOS M,GILL S,et al.Prothrombin complex concentrates for coagulopathy in liver disease:single-center,clinical experience in 105 patients[J].Hepatol Commun,2019,3(4):513-524. [92] 卜广瑞,张艳敏,李晓梅.人纤维蛋白原纠正急性白血病患者凝血功能障碍及控制出血事件的临床效果[J].血栓与止血学,2022,28(2):239-240. [93] 孟荔,黄敏,史爱武,等.人纤维蛋白原治疗产后出血的有效性和安全性[J].中国临床医生杂志,2022,50(2):214-217. [94] 中国康复技术转化及发展促进会,中国研究型医院学会关节外科学专业委员会,中国医疗保健国际交流促进会关节疾病防治分会,等.中国骨科手术加速康复围手术期氨甲环酸与抗凝血药应用的专家共识[J].中华骨与关节外科杂志,2019,12(2):81-88. [95] 李志强主编.输血医学精编[M].上海:上海交通大学出版社,2023. [96] GIORDANO P,LUCIANI M,GRASSI M,et al.Supplementation of fibrinogen concentrate in children with severe acquired hypofibrinogenaemia during chemotherapy for acute lymphoblastic leukaemia:our experience[J].Blood Transfus,2014,12(Suppl 1):s156-s157. [97] 宋铁梅,唐雅琼,张翔,等.重组人凝血因子Ⅶa治疗异基因造血干细胞移植后血小板减少合并重度出血[J].中国血液流变学杂志,2017,27(4):382-385. |
| [1] | 易萌, 樊斌, 段晓琼, 陈利民. 隐匿性乙肝感染对输血安全的影响及应对策略*[J]. 临床输血与检验, 2025, 27(2): 254-260. |
| [2] | 卿芸, 黄霞. G6PD缺乏症在输血医学中的研究进展[J]. 临床输血与检验, 2025, 27(2): 261-266. |
| [3] | 中国输血协会临床输血学专业委员会. 应对抗CD47抗体药物干扰输血相容性检测的中国专家共识*[J]. 临床输血与检验, 2025, 27(1): 13-20. |
| [4] | 刘曦, 沈雨青, 孙瑛, 张玉宇, 朱心怡, 向东. 流式方法检测患者红细胞上IgA、IgG类抗体的临床意义[J]. 临床输血与检验, 2025, 27(1): 54-58. |
| [5] | 罗圆圆, 张晓娟, 马春娅, 付丽辉, 王泽珊, 于洋. 单采血小板细菌污染致输血不良反应的病例统计分析[J]. 临床输血与检验, 2025, 27(1): 59-63. |
| [6] | 李国才, 桂嵘, 黄雪原, 屈琳, 周雄辉, 刘凤霞. 湖南省ABO血型分布及其与恶性肿瘤的相关性分析*[J]. 临床输血与检验, 2025, 27(1): 70-75. |
| [7] | 邵明, 孔永奎, 李慧娟, 田爱华, 田文亮, 周帅, 张青青, 杨乾坤. 一例过敏性输血反应疑似诱发Kounis综合征引起心率骤降的病例及文献分析[J]. 临床输血与检验, 2025, 27(1): 83-88. |
| [8] | 王金伙, 郭建荣. 自体输血对血浆麻醉药物浓度影响的相关研究进展*[J]. 临床输血与检验, 2025, 27(1): 121-126. |
| [9] | 庄远, 于洋. 输血（医学）科基于离心分离技术建立单采/血液净化治疗体系的探索[J]. 临床输血与检验, 2024, 26(6): 721-725. |
| [10] | 刘晓敏, 庄远, 于洋. 我国医疗机构输血科开展输血治疗的现状调查报告[J]. 临床输血与检验, 2024, 26(6): 740-743. |
| [11] | 王丹婷, 龙红惠, 牛迎迎, 黄春妍. 微柱凝胶法交叉配血次侧不合的原因探讨及临床意义分析[J]. 临床输血与检验, 2024, 26(6): 750-754. |
| [12] | 梁春艳, 段莉, 刘友迎, 刘方久. 住院患者输血相关循环超负荷的危险因素及预测模型的构建与验证[J]. 临床输血与检验, 2024, 26(6): 771-776. |
| [13] | 蔡茵, 陈至颖, 蒋苓, 任亚娜, 郑岚, 周国平. 上海地区无偿献血人群HLA抗体筛查分析[J]. 临床输血与检验, 2024, 26(6): 777-780. |
| [14] | 郭瑞, 侯云, 苏常山, 钟建玲, 甄志军, 何燕琴, 鲍琳, 崔立晔, 孙俊艳, 张剑, 李浩, 王振兴, 张微, 李晶, 付恒, 蔡晓波, 卢然然, 沈有华, 王登峰, 胡官林, 刘洋, 邱艳. 采用发病率-窗口期模型分析2018—2022年国内21家采供血机构输血传播HBV检测残余风险*[J]. 临床输血与检验, 2024, 26(6): 781-786. |
| [15] | 高跞, 杨懿铭, 蒋雪玉, 谢如锋, 孙娟, 杨洁. 输注异基因耐受性DC产生的外囊泡体引发输血相关急性肺损伤风险的研究*[J]. 临床输血与检验, 2024, 26(5): 592-596. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
